Skip to main content
An official website of the United States government
Email

CTD² Data Portal

The CTD² is a community resource project and network where members release their data to this Data Portal and our Dashboard for other investigators to maximize the impact of the findings. There are currently 83 datasets available from 12 centers. 

The Broad Institute

Targeting Vulnerabilities of Therapy-resistant Cancer Cell States with Small Molecules

Principal Investigator 
Stuart L. Schreiber, Ph.D.

Contact
Paul Clemons


 

Select a dataset to view details:

  1. Cancer Therapeutics Response Portal (CTRP v1, 2013) Dataset
     
  2. Cancer Therapeutics Response Portal (CTRP v2, 2015) Dataset
     
  3. Annotated Cluster Multidimensional Enrichment (ACME) Analysis
     
  4. Basal Gene-expression and Copy-number Correlation Analysis

 

Columbia University

Systematic Identification and Pharmacological Targeting in Tumor Dependencies for Precision Cancer Medicine

Principal Investigator 
Andrea Califano, Ph.D.

Contacts
Multiple Contacts

Select a dataset to view details:

  1. Computational Human High-grade Glioblastoma Multiform (GBM) Interactome - miRNA (Post-transcriptional) Layer
     
  2. Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia (T-ALL)
     
  3. Expression Profile of Neuroendocrine Tumor Cell-line Perturbed with Small Molecules
     
  4. PLATE-seq for Genome-wide Regulatory Network Analysis of High-throughput Screens
     
  5. Pharmacological Targeting of Mechanistic Dependencies in Neuroendocrine Tumors
     
  6. Core Regulatory Elements of High-risk Neuroblastoma
     
  7. Proteome-wide Signaling-network Analysis in Lung Adenocarcinoma
     
  8. CTD² Pancancer Drug Activity Challenge
     

  9. OncoLoop: A Network-based Precision Cancer Medicine Framework
     

  10. CTD² Pancancer Chemosensitivity Challenge
     

  11. NaRnEA: An Information Theoretic Framework for Gene Set Analysis
     

  12. Systematic Elucidation and Pharmacological Targeting of  Tumor-Infiltrating Regulatory T Cell Master Regulators

Dana-Farber Cancer Institute

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Principal Investigator 
William C. Hahn, M.D., Ph.D.

Contact
Joshua Dempster
 

Select a dataset to view details:

  1. Mapping the Function of Rare Oncogenic Variants
     
  2. Discovery of Resistance Mechanisms: Breast Cancer
     
  3. Discovery of Resistance Mechanisms: Colon Cancer
     
  4. Discovery of Novel Oncogenes: Ovarian Cancer
     
  5. Discovery of Novel Oncogenes: Across Cancer Types
     
  6. Discovery of Novel Oncogenes: High-grade Serous Ovarian Cancer
     
  7. Identification of Therapeutic Targets: Adult and Pediatric Cancer Types
     
  8. Identification of Therapeutic Targets Across Cancer Types: ATARiS
     
  9. Identification of Therapeutic Targets Across Cancer Types: Project Achilles
     
  10. Identification of Therapeutic Targets in KRAS Driven Lung Cancer
     
  11. Identification of Therapeutic Targets in Ovarian Cancer
     
  12. Genome-wide shRNA Screens with DEMETER Inferred Gene Effects
     
  13. Computational Correction of Copy-number Effect in CRISPR-Cas9 Screens of Cancer Cells
     
  14. SMAD4 Represses FOSL1 Expression and Pancreatic Cancer Metastatic Colonization

Emory University

Systematic Discovery of Neomorph Protein-Protein Interactions in Cancer for Oncogenic Pathway Perturbation

Principal Investigator 
Haian Fu, Ph.D.

Contact
Andrey A. Ivanov

Select a dataset to view details:

  1. High-throughput Protein-protein Interaction Analysis for Hippo Pathway Profiling
     
  2. LC-MS Analysis of PRAS40 Protein-protein Interactions
     
  3. High-throughput Protein-protein Interaction Dataset for Lung Cancer-associated Genes
     
  4. MEDICI (Mining Essentiality Data to Identify Critical Interactions) for Cancer Drug Target Discovery and Development
     
  5. Discovery of Novel MYC Protein Interactors with NanoPCA High-throughput Protein-protein Interaction Screening
     
  6. mRNA-seq Analysis of FFPE Prostate Cancer Tissues
     
  7. Identification of Protein-protein Interaction Inhibitors as Potential Anti-tumor Immunity Enhancers
     
  8. Discovering Protein-protein Interaction (PPI) Inducers to Restore the Lost Function of a Tumor Suppressor
     
  9. Discovery of the First Chemical Tools to Regulate MKK3-mediated MYC Activation in Cancer
     

  10. Systematic Discovery of Mutation-Directed Neo-Protein-Protein Interactions in Cancer

Fred Hutchinson Cancer Center

An Integrated Functional and Computational Discovery Engine for Preclinically-Validated Cancer Drug Targets 

Principal Investigator 
Christopher Kemp, Ph.D.

Contact
Russell Moser

Select a dataset to view details:

  1. Genetic Disruption of CTCF Destabilizes DNA Methylation
     
  2. Functional Landscape of the Human Kinome in MYCN Amplified and Non-amplified Neuroblastoma
     
  3. Identification of Drug Targets for Combination Therapy with Retinoic Acid in Neuroblastoma
     
  4. Functional Exploration of the Druggable Genome in MYCN Amplified and Non-amplified Neuroblastoma
     
  5. Identification of Candidate Therapeutic Targets in Head and Neck Cancer Using Functional Kinomics
     
  6. Kinome-wide siRNA Screens (screen 1) to Discover Novel Vulnerabilities in Ras/Tp53 Mutant Murine Squamous Cell Carcinomas
     
  7. Functional Exploration of the Druggable Genome in Cisplatin Resistant Ovarian Cancer
     
  8. Functional Exploration of the Kinome in MYC Driven Ovarian Cancer
     
  9. Functional Exploration of the Kinome in Pancreatic Ductal Adenocarcinoma
     
  10. Functional Exploration of the Druggable Genome in Pancreatic Ductal Adenocarcinoma
     
  11. Functional Exploration of the Druggable Genome in Head and Neck Squamous Cell Carcinoma
     
  12. Kinome-wide siRNA Screens (screen 2) to Discover Novel Vulnerabilities in Ras/Tp53 Mutant Murine Squamous Cell Carcinomas
     
  13. Identification of Novel Targets and Sensitizers to the PARP Inhibitor Rucaparib in Ovarian Cancer

Identifying and Validating Tumor-Selective Targets for use in Immunotherapy

Principal Investigator 
Martin McIntosh, Ph.D.

Contact
Martin McIntosh

Select a dataset to view details:

  1. Transcript Splicing in Ovarian Cancer and in Diverse Normal Tissues
     
  2. NanoString Profiling of MUC16 in Serous Ovarian Cancer, Benign Ovarian Tumor and Normal Tissues
     
  3. Spectral Nature of Fusion Transcripts in Serous Ovarian Cancer

Johns Hopkins University

Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastasis

Principal Investigator 
Joel S. Bader, Ph.D.

Contacts
Joel Bader
(computational methods)

Andrew Ewald
(wet-lab methods)

Select a dataset to view details:

  1. E-cadherin Promotes Metastasis in Invasive Ductal Breast Cancer
     
  2. Organoid Spectral Invasion and Population Genetics

Oregon Health and Science University

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies

Principal Investigator 
Brian J. Druker, M.D.

Contacts
Multiple Contacts

 

Select the dataset to view more details:

  1. Functional Genomic Landscape of Acute Myeloid Leukaemia
     
  2. Secondary Fusion Proteins as a Mechanism of BCR::ABL1 Kinase-independent Resistance in Chronic Myeloid Leukaemia

Integrative Bioinformatics and Functional Characterization of Oncogenic Driver Aberrations in Cancer

Principal Investigator 
Gordon Mills, M.D., Ph.D.

Contacts
Multiple Contacts

 

Select the dataset to view details:

  1. Large-scale Characterization of Drug Responses for Clinically Relevant Proteins in Cancer Cell Lines
     
  2. In Vivo Functional Characterization of EGFR Variants Identifies Novel Drivers of Glioblastoma
     
  3. Tumor-intrinsic SIRPA Promotes Sensitivity to Checkpoint Inhibition Immunotherapy in Melanoma

Stanford University

Organoid-based Discovery of Oncogenic Drivers and Associated Transformation Mechanisms

Principal Investigators 
Calvin J. Kuo, M.D., Ph.D.
Hanlee Ji, M.D.

Contacts
Multiple Contacts

Select a dataset to view details:

  1. Identifying Methylation-driven Genes in Colorectal Cancer
     
  2. Organoid Modeling of the Tumor Immune Microenvironment
     
  3. Quantifying the Timing of Metastatic Progression from Patient Genomic Data
     
  4. Single-cell Genomic Characterization of the Tumor Microenvironment of Gastric Cancer
     
  5. Predicting DNA Methylation Patterns using Histopathology Images
     
  6. A CRISPR/Cas9-engineered ARID1A-deficient Human Gastric Cancer Organoid Model Reveals Essential and Non-essential Modes of Oncogenic Transformation
     
  7. Tumor Microenvironment of Metastatic Colorectal Cancer
     
  8. Functional Screening of Amplification Outlier Oncogenes in Organoid Models of Early Tumorigenesis

Translational Genomics Research Institute (complete)

Systematic Development of Novel Druggable Targets in Glioblastoma

Principal Investigator 
Michael E. Berens, Ph.D.

Contact
Sen Peng

Select a dataset to view details:

  1. Glioblastoma Multiforme Orthotopic Xenograft Transcriptome
     
  2. Identification of Pathways Enriched with Condition-specific Statistical Dependencies Across Four Subtypes of Glioblastoma Multiforme (GBM)
     
  3. Quantified Cancer Cell Line Encyclopedia RNA-seq Data

University of California San Francisco

Transformative Strategies for Dissecting Cancer Pathways

Principal Investigator 
Michael McManus, Ph.D.

Contact
Sourav Bandyopadhyay

Select a dataset to view details:

  1. Chemical-genetic Interaction Mapping Strategy
     
  2. Construction of Directional Regulatory Networks Using Orthogonal CRISPR/Cas Screens
     
  3. A Quantitative Chemical-genetic Interaction Map of Cancer Chemotherapy

Genetic Network Analysis to Discover Cancer Targets

Principal Investigator 
William A. Weiss, M.D., Ph.D.

Contact
David Quigley

Select a dataset to view details:

  1. Integrative Genomic Approaches in Neuroblastoma (NBL)
     

  2. Expression Analysis of Superior Cervical Ganglion from Backcrossed TH-MYCN Transgenic Mice
     

  3. Gene Expression Profiling of Normal Mouse Skin, Hras WT and Hras -/-
     

  4. Human Neuroepithelial Stem Cells as a Model System for Medulloblastoma

University of Texas MD Anderson Cancer Center (complete)

Biological Annotation of Data from Large-Scale Cancer Genomic Initiatives

Principal Investigator 
Gordon B. Mills, M.D., Ph.D.

Contact
Prahlad Ram

Select a dataset to view details:

  1. Characterization of PIK3R1 Neomorphic Mutations
     
  2. High-throughput Screening Identifying Driving Mutations in Endometrial Cancer
     
  3. Phenotypic Examination of PIK3CA Allelic Series Using MCF10A Cell Sensor Platform
     
  4. Systematic Functional Annotation of Somatic Mutations in Cancer
     

  5. Informer Drug Library Screening Against Patient-derived PDGFRA Mutations

University of Texas Southwestern Medical Center (complete)

A Concerted Attack on Patient-Specific Oncogenic Vulnerabilities in Lung Cancer

Principal Investigator 
Michael Roth, Ph.D.

Contact
Bruce Posner

Select a dataset to view details:

  1. Lung Cancer Oncogenotype-selective Drug Target Discovery (Natural Products Focus)
     
  2. Functional Signature Ontology Tool: Triplicate Measurements of Reporter Gene Expression in Response to Individual Genetic and Chemical Perturbations in HCT116 Cells (Colon Cancer)
     
  3. U01 Natural Products Screening
     
  4. High-throughput siRNA Screening of a Non-small Cell Lung Cancer (NSCLC) Cell Line Panel
     
  5. Identification of ASCL1 as a Therapeutic Target for High-grade Neuroendocrine Lung Cancers
     
  6. SW04428 is a Novel Topoisomerase 1 Inhibitor
     
  7. NSCLC Cell Lines with Loss of SMARCA4 Expression are Hypersensitive to Inhibitors of Aurora Kinase A
     
  8. DRC Study of Natural Products Against Non-small Cell Lung Cancer (NSCLC) Cell Lines
     

  9. High-throughput Screening of CTD² Network Informer Set (CNIS) Compounds Against Non-Small-Cell Lung Cancer (NSCLC) Cell Lines

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “CTD² Data Portal was originally published by the National Cancer Institute.”

Email